ML 228HIF pathway activator CAS# 1357171-62-0 |
2D Structure
- BMN-673 8R,9S
Catalog No.:BCC1422
CAS No.:1207456-00-5
- XAV-939
Catalog No.:BCC1120
CAS No.:284028-89-3
- PJ34
Catalog No.:BCC1865
CAS No.:344458-19-1
- ABT-888 (Veliparib)
Catalog No.:BCC1267
CAS No.:912444-00-9
- Veliparib dihydrochloride
Catalog No.:BCC2076
CAS No.:912445-05-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1357171-62-0 | SDF | Download SDF |
PubChem ID | 46742353 | Appearance | Powder |
Formula | C27H21N5 | M.Wt | 415.49 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 20 mM in ethanol | ||
Chemical Name | 6-phenyl-N-[(4-phenylphenyl)methyl]-3-pyridin-2-yl-1,2,4-triazin-5-amine | ||
SMILES | C1=CC=C(C=C1)C2=CC=C(C=C2)CNC3=C(N=NC(=N3)C4=CC=CC=N4)C5=CC=CC=C5 | ||
Standard InChIKey | QNRODODTMXCRKU-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C27H21N5/c1-3-9-21(10-4-1)22-16-14-20(15-17-22)19-29-27-25(23-11-5-2-6-12-23)31-32-26(30-27)24-13-7-8-18-28-24/h1-18H,19H2,(H,29,30,32) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | HIF pathway activator (EC50 values are 1.23 and 1.4 μM for HRE gene reporter assay and HIF-1α nuclear translocation assay respectively); acts via chelation of iron, independently of PHD. Also exhibits > 80% inhibition of the human A3 receptor, dopamine transporter, μ receptor, hERG and 5-HT2B receptor, and rat sodium channel site 2, at a concentration of 10 μM. |
ML 228 Dilution Calculator
ML 228 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.4068 mL | 12.034 mL | 24.068 mL | 48.1359 mL | 60.1699 mL |
5 mM | 0.4814 mL | 2.4068 mL | 4.8136 mL | 9.6272 mL | 12.034 mL |
10 mM | 0.2407 mL | 1.2034 mL | 2.4068 mL | 4.8136 mL | 6.017 mL |
50 mM | 0.0481 mL | 0.2407 mL | 0.4814 mL | 0.9627 mL | 1.2034 mL |
100 mM | 0.0241 mL | 0.1203 mL | 0.2407 mL | 0.4814 mL | 0.6017 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
HIF pathway activator (EC50 values are 1.23 and 1.4 μM for HRE gene reporter assay and HIF-1α nuclear translocation assay respectively); acts via chelation of iron, independently of PHD. Also exhibits > 80% inhibition of the human A3 receptor, dopamine transporter, μ receptor, hERG and 5-HT2B receptor, and rat sodium channel site 2, at a concentration of 10 μM.
- c-Met inhibitor 1
Catalog No.:BCC1488
CAS No.:1357072-61-7
- N-Acetylglycyl-D-glutamic acid
Catalog No.:BCC6634
CAS No.:135701-69-8
- HG-14-10-04
Catalog No.:BCC5392
CAS No.:1356962-34-9
- AZD-3463
Catalog No.:BCC3907
CAS No.:1356962-20-3
- ent-3-Oxokaurane-16,17-diol
Catalog No.:BCN6188
CAS No.:135683-73-7
- Narchinol B
Catalog No.:BCN7796
CAS No.:1356822-09-7
- Fmoc-Cha-OH
Catalog No.:BCC3160
CAS No.:135673-97-1
- 17-Methylparsonsianidine
Catalog No.:BCN2093
CAS No.:135637-68-2
- CP 80633
Catalog No.:BCC7463
CAS No.:135637-46-6
- Coccineone B
Catalog No.:BCN6464
CAS No.:135626-13-0
- Fmoc-D-His(Trt)-OH
Catalog No.:BCC3504
CAS No.:135610-90-1
- Parsonsianidine
Catalog No.:BCN2109
CAS No.:135601-81-9
- MDL 29,913
Catalog No.:BCC5729
CAS No.:135721-56-1
- Palonosetron
Catalog No.:BCC1834
CAS No.:135729-61-2
- Palonosetron hydrochloride
Catalog No.:BCN2171
CAS No.:135729-62-3
- Taxinine M
Catalog No.:BCN6942
CAS No.:135730-55-1
- OG-L002
Catalog No.:BCC4549
CAS No.:1357302-64-7
- Nonin A
Catalog No.:BCN7149
CAS No.:1357351-29-1
- RGFP966
Catalog No.:BCC3991
CAS No.:1357389-11-7
- Boc-Glu(OBzl)-OH
Catalog No.:BCC3389
CAS No.:13574-13-5
- Isoforsythiaside
Catalog No.:BCN5413
CAS No.:1357910-26-9
- Koumine
Catalog No.:BCN6190
CAS No.:1358-76-5
- erythro-Guaiacylglycerol beta-dihydroconiferyl ether
Catalog No.:BCN7025
CAS No.:135820-77-8
- Blumenol C glucoside
Catalog No.:BCN6189
CAS No.:135820-80-3
Suicidal Ideation vs. Suicide Attempts: Clinical and Psychosocial Profile Differences Among Depressed Patients: A Study on Personality Traits, Psychopathological Variables, and Sociodemographic Factors in 228 Patients.[Pubmed:28225508]
J Nerv Ment Dis. 2017 May;205(5):361-371.
This study investigated whether personality traits, psychopathological characteristics, and sociodemographic factors in depressed patients differentiate patients with only suicidal thoughts from those who have attempted suicide. We investigated two groups of patients with an affective disorder: 198 patients with a suicide attempt within the last 3 months (sex ratio male to female, 1:1.3; mean age male to female, 44.8/44.7 years) and 30 patients without a suicide attempt but with suicidal thoughts (sex ratio male to female, 1:2; mean age male to female, 39.4/42.6 years) using a comprehensive measurement (Mini-International Neuropsychiatric Interview, Structured Clinical Interview for DSM-4 Axis II disorders, Hamilton Depression Scale, Beck Depression Inventory, State-Trait Anxiety Inventory, Hamilton Anxiety Scale, Brief Psychiatric Rating Scale, Clinical Global Impression Scale, Beck-Hopelessness Scale, Scale for Suicide Ideation, Impulsivity Rating Scale, Barratt Impulsivity Scale, Inventory for the Assessment of Aggression Factors, State-Trait Anger Expression Inventory, Ways of Coping Checklist). Several differences distinguished the two groups, namely, in personality traits such as anxiety or coping strategies and sociodemographics (e.g., education level). Personality traits, psychopathological characteristics, and sociodemographic factors are useful tools for assessing suicidal risk. Our findings encourage us to suggest that clinicians pay particular attention to sociodemographic variables such as separation/divorce and a lower education level when conducting risk assessments on suicidal patients.
The educational gradient in cardiovascular risk factors: impact of shared family factors in 228,346 Norwegian siblings.[Pubmed:28356092]
BMC Public Health. 2017 Mar 30;17(1):281.
BACKGROUND: Various indicators of childhood socioeconomic position have been related to cardiovascular disease (CVD) risk in adulthood. We investigated the impact of shared family factors on the educational gradient in midlife CVD risk factors by assessing within sibling similarities in the gradient using a discordant sibling design. METHODS: Norwegian health survey data (1980-2003) was linked to educational and generational data. Participants with a full sibling in the health surveys (228,346 individuals in 98,046 sibships) were included. Associations between attained educational level (7-9 years, 10-11 years, 12 years, 13-16 years, or >16 years) and CVD risk factor levels in the study population was compared with the corresponding associations within siblings. RESULTS: Educational gradients in risk factors were attenuated when factors shared by siblings was taken into account: A one category lower educational level was associated with 0.7 (95% confidence interval 0.6 to 0.8) mm Hg higher systolic blood pressure (27% attenuation), 0.4 (0.4 to 0.5) mmHg higher diastolic blood pressure (30%), 1.0 (1.0 to 1.1) more beats per minute higher heart rate (21%), 0.07 (0.06 to 0.07) mmol/l higher serum total cholesterol (32%), 0.2 (0.2 to 0.2) higher smoking level (5 categories) (30%), 0.15 (0.13 to 0.17) kg/m(2) higher BMI (43%), and 0.2 (0.2 to 0.2) cm lower height (52%). Attenuation increased with shorter age-difference between siblings. CONCLUSION: About one third of the educational gradients in modifiable CVD risk factors may be explained by factors that siblings share. This implies that childhood environment is important for the prevention of CVD.
Discovery of a new molecular probe ML228: an activator of the hypoxia inducible factor (HIF) pathway.[Pubmed:22172704]
Bioorg Med Chem Lett. 2012 Jan 1;22(1):76-81.
Hypoxia and ischemia are linked to several serious public health problems that affect most major organ systems. Specific examples include diseases of the cardiovascular, pulmonary, renal, neurologic, and musculoskeletal systems. The most significant pathway for cellular response to hypoxia is the hypoxia inducible factor (HIF) pathway. HIFs are transcription factors responsible for the activation of genes which encode proteins that mediate adaptive responses to reduced oxygen availability. A high-throughput cell-based HIF-mediated gene reporter screen was carried out using the NIH's Molecular Libraries Small Molecule Repository to identify activators of the HIF pathway. This communication describes the subsequent medicinal chemistry optimization of a triazine scaffold that led to the identification of the new molecular probe ML228. A discussion of HIF activation SAR within this chemotype as well as detailed in vitro characterization of the probe molecule is presented here.